Compare EDUC & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EDUC | OSRH |
|---|---|---|
| Founded | 1965 | N/A |
| Country | United States | United States |
| Employees | N/A | 21 |
| Industry | Consumer Specialties | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7M | 11.7M |
| IPO Year | 1995 | N/A |
| Metric | EDUC | OSRH |
|---|---|---|
| Price | $1.42 | $0.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 34.3K | ★ 781.5K |
| Earning Date | 05-19-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $34,191,000.00 | N/A |
| Revenue This Year | N/A | $9.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.01 | $0.38 |
| 52 Week High | $1.84 | $1.79 |
| Indicator | EDUC | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 66.22 | 42.09 |
| Support Level | $1.25 | $0.44 |
| Resistance Level | $1.42 | $0.63 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 64.71 | 11.96 |
Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.